Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease

Clinical Respiratory Journal

Volumn 6, Issue 1, 2012, Pages 9-17

  De Santis, Maria ^a   Bosello, Silvia Laura ^a   Peluso, Giusy ^a   Pinnelli, Michela ^a   Alivernini, Stefano ^a   Zizzo, Gaetano ^a   Bocci, Mario ^a   Capacci, Annunziata ^a   La Torre, Giuseppe ^a   Mannocci, Alice ^a   Pagliari, Gabriella ^a   Varone, Francesco ^a   Pistelli, Roberto ^a   Danza, Francesco Maria ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alveolitis; Honeycombing; Interstitial lung disease; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE;

ADULT; AGED; ARTICLE; DISEASE COURSE; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG FUNCTION TEST; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGICAL PARAMETERS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL TIME; SYSTEMIC SCLEROSIS;

ANTIBODIES; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD19; BRONCHOALVEOLAR LAVAGE FLUID; CD4-CD8 RATIO; DISEASE PROGRESSION; DNA TOPOISOMERASES; EOSINOPHILS; FEMALE; HUMANS; LOGISTIC MODELS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RISK FACTORS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84055212479     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2010.00228.x     Document Type: Article

References (34)

1. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37: 1283-9.
2. Antoniou KM, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol. 2008; 20: 686-91.
3. De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, Pistella R, Danza FM, Zogi A, Ferraccioli G. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005; 17(6): 96-102.
4. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Aslam PL, Vassilakis DA, Black CM, de Bois RM. Histopathologic subset of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165: 1581-6.
5. Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology. 2008;47.
6. Launay D, Remy-Jardin M, Michon-Pasturel U etal. High resolution computer tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol. 2006;33(9): 1789-801.
7. Flaherty KR, Thwaite EL, Kazerooni EA etal. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58: 143-8.
8. Goh NSL, Desai SR, Veerarhagavan S etal. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177: 1248-54.
9. Behr J, Vogelmeier C, Beinert T, Meurer M, Krombach F, Konig G, Fruhmann G. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154: 400-6.
10. White B, Moore W, Wigley F, Xiao HQ, Wise R. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132: 947-54.
11. Tashkin DP, Elashoff R, Clements PJ etal. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66.
12. Baughman RP, Raghu G. Bronchoalveolar cellular analysis in scleroderma lung disease: does Sutton's law hold? Am J Respir Crit Care Med. 2008;177: 2-3.
13. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, etal. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Res Crit Care Med. 2007; 177(1): 91-8.
14. Goh NSL, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56(6): 2005-12.
15. Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Sem. Arthritis Rheum. 2010;40: 73-88.
16. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23: 581-90.
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis. J Rheumatol. 1988;15: 202-5.
18. Reveille JD, Solomon DH and ACR ad hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70 and nucleolar antibodies. Arthritis Rheum. 2003;49: 399-412.
19. American Thoracic Society. Standardization of Spirometry-1994 Update. Am J Respir Crit Care Med. 1995;152: 1107-36.
20. American Thoracic Society. Single breath carbon monoxide diffusing capacity. (transfer factor). Recommendation for a standard technique - 1995 update. Am J Respir Crit Care Med. 1995;152: 2185-98.
21. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005;60: 270-3.
22. Behr J, Furst DE. Pulmonary function tests. Rheumatol. 2008;47: v65-7.
23. Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis in SSc. Clin Exp Rheumatol. 2003;S29: 42-6.
24. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group on BAL. Eur Respir J. 1989;2: 561-85.
25. Baker AM, Bowton DL, Haponik EF. Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantitative bronchoscopic cultures. Chest. 1995;107: 85-95.
26. The Joint Statement of the ATS and ETS. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161: 646-64.
27. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, etal. Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest. 2008;134(2): 358-67.
28. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, etal. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum. 2005;53(4): 549-57.
29. Merchant RK, Schwartz DA, Helmersra RA, Dayton CS, Hunninghake GW. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis. 1992;146: 448-53.
30. Domagala-Kulawik J, Hoser G, Kawalect M, Doboszynska A, Kawiak J, Droszcz W. Lymphocyte phenotyping in systemic sclerosis. A flow cytometry analysis of lymphocytes in bronchoalveolar lavage fluid. Anal Quant Cytol Histol. 1997;19: 264-70.
31. Domagala-Kulawik J, Hoser G, Doboszynska A, Kawiak J, Droszcz W. Interstitial lung disease in systemic sclerosis: comparison of BALF lymphocytes phenotype and DLCO impairment. Respir Med. 1998;92: 1295-301.
32. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol. 2005;17(6): 746-51.
33. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 2007;56(9): 3167-8.
34. Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, etal. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum. 1999;42(6): 1168-78.